Search

MSK’s SPORE grant in leukemia has the potential to develop practice-changing approaches, evaluation, and management that may lead to improved patient outcomes for AML.

… Tuesday, September 7, 2021 The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone

Memorial Sloan Kettering’s 42nd annual ceremony recognized graduates and award winners with a virtual ceremony.

… Thursday, May 20, 2021 Memorial Sloan Kettering’s 42nd annual Academic Convocation and Commencement ceremony, which took place on May 19, 2021, was held virtually for a second year due to the COVID-19 pandemic. Four members of MSK’s leadership team took to the stage in the Zuckerman Research Center,

At Memorial Sloan Kettering Cancer Center, we have now analyzed more than 50,000 samples in our prospective cohort with MSK-IMPACT™.

… Wednesday, February 24, 2021 At Memorial Sloan Kettering Cancer Center, we have now analyzed over 65,000 samples in our prospective cohort with MSK-IMPACT™ , our next-generation sequencing (NGS) platform, and are adding to that number every day. This is up 8000 from January this year, despite Covid-19

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology; Grayer Family Chair at MSK, has been elected to the 10th class of Giants of Cancer Care® for his contributions in translational science.

… Monday, May 9, 2022 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology; Grayer Family Chair at MSK, has been elected to the 10 th class of Giants of Cancer Care® for his contributions in translational science. The

Learn how immune cells in the lungs trigger invasive fungal cells to self-destruct. The discovery could produce therapies to prevent infection in cancer patients.

… Thursday, September 7, 2017 Summary Due to their weakened immune function, cancer patients who receive bone marrow transplants are at a high risk of infection from a common fungus called Aspergillus fumigatus . Researchers discovered that immune cells in the lungs of healthy people kill the fungal cells

Learn how Memorial Sloan Kettering Cancer Center kept caring for patients during the response to COVID-19, and how lessons learned during the pandemic are helping cancer care.

… Thursday, October 1, 2020 “It felt like watching a terrifying storm moving toward us in slow motion.” That is how Memorial Sloan Kettering lymphoma doctor Matthew Matasar describes watching the COVID-19 pandemic unfold. MSK doctors, researchers, and staff never wavered in their commitment to continue

Hear from five Fred’s Team members about why they’re running the New York City Marathon in 2017.

… Tuesday, October 31, 2017 Laura, a Fred’s Team runner “I dedicate my miles to my family, friends, coworkers, and the amazing team at MSK, because even though there were times when my cancer diagnosis felt incredibly scary, they were there for me every step of the way. I run in celebration of how far

Read how genetic differences affect levels of Epstein Barr Virus in the body and the risk of certain chronic diseases.

… Wednesday, January 28, 2026 A virus you likely carry could hold clues to your future health. Epstein-Barr virus (EBV) infects nearly everyone, and for most people it hides quietly in the body for life. But for some, this common virus can do far more than linger and is linked to increased risk of developing

Mysterious circular DNA may contribute to neuroblastoma and other childhood cancers.

… Monday, December 16, 2019 Summary Researchers have long been puzzled by rings of DNA that lie outside chromosomes in cells. A new study suggests that DNA from these circles inserts itself into chromosomes and triggers the uncontrolled cell growth that is the hallmark of cancer. People typically visualize

Updated survival outcomes from the EMBER-3 trial reinforced the clinical benefit of imlunestrant-based regimens as all-oral, chemotherapy-free treatment options for endocrine-pretreated patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Breast medical oncologist Komal Jhaveri, MD, FACP, presented the latest results for the trial at SABCS, and was also the lead and corresponding author of the paper published simultaneously in the Annals of Oncology.

… Friday, December 12, 2025 Updated survival outcomes from the EMBER-3 trial reinforced the clinical benefit of imlunestrant as monotherapy and in combination with abemaciclib as oral, chemotherapy-free treatment options for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor